Ftse Mib
34.019,58
-1,11%
DAX
20.057,20
-1,01%
S&P 500
5.872,16
0,00%
NASDAQ
19.392,69
0,00%
Bitcoin
101.961,16
1,90%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lipella Pharmaceuticals Inc (LIPO) Lipella Pharmaceuticals Inc (LIPO) Notizie

Lipella Pharmaceuticals Inc

LIPO
2,61
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:04:01
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/12/202415:29EDGAR2Form 8-K - Current report
06/12/202422:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/12/202422:05EDGAR2Form 8-K - Current report
03/12/202414:30GLOBELipella Pharmaceuticals Announces Publication in CUREUS on..
21/11/202411:30GLOBELipella Pharmaceuticals Announces Completion of First Cohort..
14/11/202423:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202423:09EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202423:00EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202411:30GLOBELipella Pharmaceuticals Secures Extended Market Exclusivity..
07/11/202423:01EDGAR2Form 8-K - Current report
01/11/202422:24EDGAR2Form PRE 14A - Other preliminary proxy statements
01/11/202422:00EDGAR2Form 8-K - Current report
01/11/202421:30GLOBELipella Pharmaceuticals Announces 1-for-8 Reverse Stock..
29/10/202413:30GLOBELipella Pharmaceuticals to Present at 2024 Spartan Capital..
18/10/202422:05EDGAR2Form 8-K - Current report
17/10/202423:00EDGAR2Form SC 13D/A - General Statement of Acquisition of..
17/10/202423:00EDGAR2Form SC 13D/A - General Statement of Acquisition of..
15/10/202411:00GLOBELipella Pharmaceuticals Announces U.S. Patent Allowance for..
09/10/202416:47GLOBELipella Pharmaceuticals to Present at 2024 Maxim Healthcare..
25/9/202414:30GLOBEPRISM MarketView Features Q&A with Dr. Michael Chancellor:..
24/9/202414:00GLOBELipella Pharmaceuticals Reports Encouraging Early..
11/9/202423:10EDGAR2Form 8-K - Current report
27/8/202414:00GLOBELipella Pharmaceuticals to Participate at H.C. Wainwright's..
23/8/202422:45EDGAR2Form 8-K - Current report
22/8/202411:00GLOBELipella Pharmaceuticals Launches Innovative Registry to..
21/8/202411:00GLOBELipella Pharmaceuticals Unveils Advanced Bladder Imaging..
19/8/202422:05EDGAR2Form SC 13D/A - General Statement of Acquisition of..
13/8/202422:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202414:44EDGAR2Form ARS - Annual Report to Security Holders
12/8/202414:25EDGAR2Form DEF 14A - Other definitive proxy statements
12/8/202411:00GLOBELipella Pharmaceuticals Doses First Two Patients in Phase 2a..
06/8/202422:50EDGAR2Form 8-K - Current report
01/8/202423:20EDGAR2Form 8-K - Current report
01/8/202422:05GLOBELipella Pharmaceuticals Announces Closing of $1.28 Million..
01/8/202417:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/8/202414:00GLOBELipella Pharmaceuticals Announces $1.28 Million Registered..
30/7/202422:05EDGAR2Form PRE 14A - Other preliminary proxy statements
29/7/202411:00GLOBELipella Pharmaceuticals Initiates Phase 2a Trial for LP-310..
31/5/202414:00GLOBELipella Pharmaceuticals Announces Completion of Site..
29/5/202414:00GLOBELipella Pharmaceuticals Announces Abstract Publication at..
21/5/202414:00GLOBEFollowing Guidance from U.S. Food & Drug Administration in..
15/5/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202422:05EDGAR2Form SC 13D/A - General statement of acquisition of..
17/4/202414:00GLOBELipella Pharmaceuticals Expands its Advisory Board to..
05/4/202414:00GLOBELipella Pharmaceuticals to Publish Abstract Detailing..
03/4/202414:00GLOBELipella Pharmaceuticals Announces FDA Type C Meeting for..
07/3/202421:23GLOBEPRISM MarketView Spotlights Lipella Pharmaceuticals as it..
06/3/202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
06/3/202423:03EDGAR2Form SC 13D/A - General statement of acquisition of..
Apertura: Min: Max:
Chiusura: 2,61

La tua Cronologia

NASDAQ
LIPO
Lipella Pharmaceuticals
BIT
HERU
Global X Video Game & Es...
LSE
60CX
Hdfc.bk 23
BIT
SENIL5
Sg Issuer
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network